Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli, L. Gugliotta, R. Landolfi, J. Kutti, H. Gisslinger, R. Marilus, C. Patrono, E. Pogliani, M. Randi, A. Villegas, G. Tognoni, T. Barbui (2005)Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.
Blood, 105 7
J. Mascarenhas, N. Roper, P. Chaurasia, R. Hoffman (2011)Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
Clinical Epigenetics, 2
P. Berk, J. Goldberg, M. Silverstein, A. Weinfeld, Donovan Pb, Ellis Jt, Landaw Sa, J. Laszlo, Y. Najean, A. Pisciotta, L. Wasserman (1981)Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
The New England journal of medicine, 304 8
J. Mascarenhas, M. Heaney, V. Najfeld, E. Hexner, O. Abdel-Wahab, R. Rampal, F. Ravandi, B. Petersen, G. Roboz, E. Feldman, N. Podoltsev, D. Douer, R. Levine, M. Tallman, R. Hoffman (2012)Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Leukemia research, 36 12
(1966)Guglielmo’s syndrome after polycythemia
O. Abdel-Wahab, T. Manshouri, Jay Patel, K. Harris, Jinjuan Yao, C. Hedvat, A. Heguy, C. Bueso-Ramos, H. Kantarjian, R. Levine, S. Verstovsek (2010)Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Cancer research, 70 2
B. Druker (2009)Perspectives on the development of imatinib and the future of cancer research
Nature Medicine, 15
R. Levine, M. Wadleigh, J. Cools, B. Ebert, G. Wernig, B. Huntly, T. Boggon, I. Wlodarska, Jennifer Clark, Sandra Moore, J. Adelsperger, Sumin Koo, Jeffrey Lee, S. Gabriel, T. Mercher, A. D’Andrea, S. Fröhling, K. Döhner, P. Marynen, P. Vandenberghe, R. Mesa, A. Tefferi, J. Griffin, M. Eck, W. Sellers, M. Meyerson, T. Golub, Stephanie Lee, D. Gilliland (2005)Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Cancer cell, 7 4
N. Thoennissen, U. Krug, D. Lee, N. Kawamata, G. Iwanski, T. Lasho, T. Weiss, D. Nowak, M. Koren-Michowitz, Motohiro Kato, M. Sanada, L. Shih, A. Nagler, Sophie Raynaud, C. Müller-Tidow, R. Mesa, T. Haferlach, D. Gilliland, A. Tefferi, S. Ogawa, H. Koeffler (2009)Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
Blood, 115 14
Sujiang Zhang, R. Rampal, T. Manshouri, Jay Patel, Nana Mensah, Andrew Kayserian, Todd Hricik, A. Heguy, C. Hedvat, M. Gönen, H. Kantarjian, R. Levine, O. Abdel-Wahab, S. Verstovsek (2012)Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Blood, 119 19
Ye Ding, Y. Harada, J. Imagawa, A. Kimura, H. Harada (2009)AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
Blood, 114 25
Chad Cherington, J. Slack, J. Leis, R. Adams, C. Reeder, J. Mikhael, J. Camoriano, P. Noel, V. Fauble, Jeffrey Betcher, M. Higgins, Ginger Gillette-Kent, Lisa Tremblay, Mary Peterson, J. Olsen, R. Tibes, R. Mesa (2012)Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Leukemia research, 36 9
(2008)Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia
J. Mascarenhas, S. Navada, Adriana Malone, Amy Rodriguez, V. Najfeld, R. Hoffman (2010)Therapeutic options for patients with myelofibrosis in blast phase.
Leukemia research, 34 9
R. Mesa, chin-Yang Li, R. Ketterling, G. Schroeder, R. Knudson, A. Tefferi (2005)Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
Blood, 105 3
P. Campbell, E. Baxter, P. Beer, L. Scott, A. Bench, B. Huntly, W. Erber, R. Kušec, T. Larsen, S. Giraudier, M. Bousse-Kerdilès, M. Griesshammer, J. Reilly, B. Cheung, C. Harrison, A. Green (2006)Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
Blood, 108 10
F Passamonti, E Rumi, L Arcaini (2005)Leukemic transformation of polycythemia vera: a single center study of 23 patients
A. Harutyunyan, T. Klampfl, M. Cazzola, R. Kralovics (2011)p53 lesions in leukemic transformation.
The New England journal of medicine, 364 5
S. Thépot, R. Itzykson, V. Seegers, E. Raffoux, B. Quesnel, Y. Chait, L. Sorin, F. Dreyfus, T. Cluzeau, J. Delaunay, L. Sanhes, V. Eclache, C. Dartigeas, P. Turlure, S. Harel, C. Salanoubat, J. Kiladjian, P. Fenaux, L. Adès (2010)Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Blood, 116 19
C. Tam, R. Nussenzveig, U. Popat, C. Bueso-Ramos, D. Thomas, Jorge Cortes, R. Champlin, S. Ciurea, T. Manshouri, S. Pierce, H. Kantarjian, S. Verstovsek (2008)The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Blood, 112 5
A. Eghtedar, S. Verstovsek, Z. Estrov, J. Burger, J. Cortes, C. Bivins, S. Faderl, A. Ferrajoli, G. Borthakur, S. George, P. Scherle, R. Newton, H. Kantarjian, F. Ravandi (2012)Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood, 119 20
Skversky Nj, Yarrow Mw, Lewinn Eb (1957)Phenylbutazone in the treatment of deep-vein thrombophlebitis; a preliminary report.
The Journal of the Albert Einstein Medical Center, Philadelphia, 5
M. Björkholm, A. Derolf, M. Hultcrantz, S. Kristinsson, C. Ekstrand, L. Goldin, B. Andreasson, G. Birgegard, O. Linder, C. Malm, B. Markevärn, L. Nilsson, J. Samuelsson, F. Granath, O. Landgren (2011)Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 17
A. Tefferi, T. Lasho, O. Abdel-Wahab, P. Guglielmelli, J. Patel, D. Caramazza, L. Pieri, C. Finke, O. Kilpivaara, M. Wadleigh, M. Mai, R. Mcclure, D. Gilliland, R. Levine, A. Pardanani, A. Vannucchi (2010)IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
K. Abdulkarim, F. Girodon, P. Johansson, M. Maynadie, J. Kutti, P. Carli, Emeline Bovet, B. Andreasson (2009)AML transformation in 56 patients with Ph− MPD in two well defined populations
European Journal of Haematology, 82
A. Bank, P. Larsen, H. Anderson (1966)Di Guglielmo's syndrome after polycythemia.
The New England journal of medicine, 275 9
Ana Puda, J. Milosevic, T. Berg, T. Klampfl, A. Harutyunyan, B. Gisslinger, E. Rumi, D. Pietra, L. Malcovati, C. Elena, M. Doubek, M. Steurer, N. Tosic, S. Pavlovic, P. Guglielmelli, L. Pieri, A. Vannucchi, H. Gisslinger, M. Cazzola, R. Kralovics (2012)Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
American Journal of Hematology, 87
E. Baxter, L. Scott, P. Campbell, C. East, N. Fourouclas, S. Swanton, G. Vassiliou, A. Bench, E. Boyd, N. Curtin, M. Scott, W. Erber, A. Green (2005)Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
The Lancet, 365
S. Fruchtman, K. Mack, Marcelle Kaplan, P. Peterson, Berk Pd, L. Wasserman (1997)From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Seminars in hematology, 34 1
R. Zhao, Shu Xing, Zhe Li, Xueqi Fu, Qingshan Li, S. Krantz, Z. Zhao (2005)Identification of an Acquired JAK2 Mutation in Polycythemia Vera*
Journal of Biological Chemistry, 280
P. Beer, F. Delhommeau, J. Lecouédic, M. Dawson, E. Chen, D. Bareford, R. Kušec, M. McMullin, C. Harrison, A. Vannucchi, W. Vainchenker, A. Green (2010)Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Blood, 115 14
O. Abdel-Wahab, A. Pardanani, R. Rampal, T. Lasho, R. Levine, A. Tefferi (2011)DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
Jocelin Huang, chin-Yang Li, R. Mesa, Wentling Wu, C. Hanson, A. Pardanani, A. Tefferi (2008)Risk factors for leukemic transformation in patients with primary myelofibrosis
F. Passamonti, E. Rumi, L. Arcaini, C. Castagnola, M. Lunghi, P. Bernasconi, M. Porta, Nora Columbo, C. Pascutto, M. Cazzola, M. Lazzarino (2005)Leukemic transformation of polycythemia vera
A. Tefferi, J. Vardiman (2008)Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Acute myeloid leukemia (AML) is an uncommon, but often deadly complication of myeloproliferative neoplasms (MPN). Post-MPN AML usually occurs years after the initial MPN diagnosis with an average age of onset between 64 and 68 years. Chromosome abnormalities are common and many patients have cytogenetic changes that are associated with poor risk features. Post-MPN AML is characterized by acquired somatic gene mutations, but, interestingly, mutations thought to have an etiologic role in the MPN, such as JAK2V617F, are sometimes absent in the AML clone. Conventional AML-style treatment appears to have limited efficacy, although when coupled to allogeneic stem cell transplantation, some patients have long-term survival. Less-intensive therapies such as hypomethylating agents and the JAK inhibitor, ruxolitinib, may be effective in some patients. New treatments have prompted efforts to characterize therapeutic responses better.
Current Hematologic Malignancy Reports – Springer Journals
Published: Apr 10, 2013
Access the full text.
Sign up today, get DeepDyve free for 14 days.